For patients with AML having a germline CEBPA mutation, HSCT in CR1 is not routinely recommended because of modest survival outcome after chemotherapy and the risk of morbidity and mortality after HSCT (12, 21, 45). This evidence concerns the gene CEBPA and acute myeloid leukemia.